Keystone eSymposia Logo

Innovative Vaccine Approaches

June 28-30, 2021 | 9:00AM EDT | 1:00PM UTC | 3:00PM CEST*
*Program is in development and subject to change


   

Sust. Benefactor

AstraZeneca R&D High Level Overview:

We are driven by science, united by science, and every day, we push the boundaries of science to deliver life-changing medicines.

Link for more information: https://www.astrazeneca.com/r-...

Microbial Sciences:

Our business model thrives on being dynamic and partly externalized, with a firm focus on driving science in our key areas of interest. Early, flexible partnering with the brightest and best in the world allows us to combine knowledge and progress clinical development, while managing the challenges associated with neuroscience and microbial science research.

Link for more information: https://www.astrazeneca.com/r-...

CVRM:

We are committed to defining new standards of care for patients with cardiovascular disease, heart failure, metabolic diseases, such as diabetes and non-alcoholic steatohepatitis (NASH), and chronic kidney disease (CKD) - improving their outcomes and decreasing mortality rates.

Link for more information: https://www.astrazeneca.com/ou...

Respiratory / Immunology:

We are aiming to transform the treatment of respiratory diseases, with our growing portfolio of inhaled combinations at the core of care, biologics for the unmet needs of specific patient populations, and scientific advancements in disease modification.

Link for more information: https://www.astrazeneca.com/ou...

 
Benefactor

We aspire to be the premier research-intensive biopharmaceutical company in the world

For more than 125 years, Merck (known as MSD outside of the U.S. and Canada) has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives.

We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships.

Today, we continue to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases, such as HIV and Ebola, and emerging animal diseases.

 
Sust. Sponsor

Welcome to Moderna 

We believe mRNA is the “software of life."

Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease.

Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients.

We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured.

Since our founding in 2010, we have worked to build the industry's leading mRNA technology platform, the infrastructure to accelerate drug discovery and early development, a rapidly expanding pipeline, and a world-class team. Our pipeline includes development candidates for mRNA-based vaccines and therapies spanning several therapeutic areas, and we have multiple clinical trials underway with other development candidates progressing toward the clinic. In addition, we have numerous discovery programs advancing toward development.

Moderna's Mission:
Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.